Cancer treatment can lead to various dermatologic pathologies in need of therapy. In these often difficult-to-treat disorders, omalizumab could be a safe and efficacious addition to the current armamentarium .
In case of difficult-to-treat dermatologic adverse events (AEs) in the course of targeted therapy and immunotherapy for cancer, dermatologists are in demand for consultations. Dermatologic AEs often affect the quality of life of the cancer patients as first-line symptomatic treatment may fail to alleviate the burden of conditions such as urticaria or eczema. A retrospective study was conducted with single-centre data from electronic medical records from 48 cancer patients to assess omalizumab as a possible treatment for these side effects.
Of the 48 participants included, 75% suffered from moderate dermatologic AEs and 25% had severe dermatologic pathologies. In 54% of the cases, these events were caused by cancer treatment with anti-progra...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« Can gene expression help to pick the right biologic to treat psoriasis in cancer patients? Next Article
A new topical PDE-4 inhibitor effective in psoriasis »
Table of Contents: AAD 2020
Psoriasis – What Is Hot?
Systemic Therapies for Dermatologists
Hidradenitis Suppurativa/Acne Inversa
Pearls of the Posters
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.